Managing Bone Health in Metastatic Breast Cancer
Published Online: Friday, September 6, 2013
For High-Definition, ClickTwo agents, denosumab (Xgeva) and zoledronic acid (Zometa), are currently approved to help reduce the incidence of skeletal-related events (SREs) in patients with metastatic breast cancer (MBC). Each of these agents has a unique set of clinical parameters.
Certain factors make the administration of denosumab more convenient, such as the agent being a subcutaneous injection rather than intravenous, like zoledronic acid, notes Joyce A. O'Shaughnessy, MD. Additionally, renal toxicity is not a concern with denosumab, as it is with zoledronic acid. However, the clinical trials investigating denosumab only provide data for a few years of administration. As a result, the safety and efficacy for the extended use of this agent remains unclear.
Osteonecrosis of the jaw (ONJ) is a low frequency side effect for both of these treatments. As patients remain on these agents longer, the risk of developing this side effect increases. In many situations, ONJ occurs beyond two years; as a result, taking a treatment break may effectively reduce the risk of developing this side effect.
Before the approval of these agents patients were regularly admitted to the hospital for hypocalcaemia, points out Andrew D. Seidman, MD. While ONJ can be severe, these agents have made a substantial impact on bone health for patients with MBC.
View More From This Discussion
Sara Hurvitz, MDAssistant Professor & Director,
Hematology/Oncology Breast Cancer Program, UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California
Joyce A. O’Shaughnessy, MDCo-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Edith A. Perez, MDDeputy Director of the Mayo Clinic Cancer Center, Director of the Breast Cancer Translational Genomics Program and the Breast Program at Mayo Clinic,
Hope S. Rugo, MDProfessor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, California
Andrew D. Seidman, MDProfessor of Medicine, Weill Cornell Cancer Center, Attending Physician at Memorial Sloan Kettering Cancer Center,
New York, New York
Most Popular Right Now
Online CME Activities
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.